EMEA-003077-PIP01-21

Key facts

Invented name
COVID-19 Vaccine (inactivated, adjuvanted) Valneva
Active substance
SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001)
Therapeutic area
Vaccines
Decision number
P/0184/2022
PIP number
EMEA-003077-PIP01-21
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intramuscular use
Contact for public enquiries
Valneva Austria GmbH

E-mail: medinfo@valneva.com
Tel. +43 20620-1124

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

Related content

How useful was this page?

Add your rating
Average
3 ratings
1 rating
1 rating